Issuance of US Patents that cover GenrAb’s lead antibody therapy (TGM-010)

The Company is expanding its patent estate that includes two issued US patents 11,518,800 & 11,999,778 that cover the Company’s novel lead antibody (Ab) candidate (TGM-010) and its use as a neuroprotective and therapeutic antibody. Issued claims include the human antibody composition, and fragments thereof, that was identified as anti-neuronal in patients undergoing active neurological disease. As GenrAb further elucidated the mechanism of action for TGM-010 it has filed more broadly on its impact on neuronal stress management and is in process for supporting additional claims to new therapeutic indications. This patent portfolio has been exclusively licensed from the University of Texas Southwestern (UTSW) and is being actively augmented both internally and by Sponsored Research in the labs of Dr. Nancy Monson where additional unique Abs are being discovered and characterized.